Merck & Co., Inc. Proceeds from Sale of Equity Method Investments
Merck & Co., Inc. (MRK) reported Proceeds from Sale of Equity Method Investments of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2017-02-28
- Merck & Co., Inc. proceeds from sale of equity method investments for the quarter ending 2015-12-31 was $0.00.
- Merck & Co., Inc. proceeds from sale of equity method investments for the quarter ending 2015-09-30 was $0.00.
- Merck & Co., Inc. proceeds from sale of equity method investments for the quarter ending 2014-12-31 was $0.00.
- Merck & Co., Inc. proceeds from sale of equity method investments for the quarter ending 2014-09-30 was $0.00.
- Merck & Co., Inc. proceeds from sale of equity method investments for fiscal 2016 was $0.00.
- Merck & Co., Inc. proceeds from sale of equity method investments for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- Merck & Co., Inc. proceeds from sale of equity method investments for fiscal 2014 was $419.00M.
- Merck & Co., Inc. proceeds from sale of equity method investments for fiscal 2013 was $0.00.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month | Proceeds from Sale of Equity Method Investments 12 month | Proceeds from Sale of Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 | ||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $419.00M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $419.00M 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | $419.00M 10-Q · filed 2015-08-06 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | |||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 | ||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-27 | ||||
| 2011-12-31 | $175.00M 10-K · filed 2014-02-27 | ||||
| 2010-12-31 | $647.00M 10-K · filed 2011-02-28 | ||||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $4.00B 10-K · filed 2012-02-28 | $0.00 10-K · filed 2010-03-01 | ||
| 2009-09-30 | $4.00B 10-Q · filed 2010-11-08 | ||||
| 2008-12-31 | $1.90B 10-K · filed 2011-02-28 | $1.90B 10-K · filed 2010-03-01 | |||
| 2007-12-31 | $0.00 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |